Synairgen Company Description

Synairgen plc discovers and develops drugs for respiratory diseases.

It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses.

Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Synairgen plc

Country	United Kingdom
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	36
CEO	Richard Marsden

Contact Details

Address: Mailpoint 810 Southampton, SO16 6YD United Kingdom
Phone	44 23 8051 2800
Website	synairgen.com

Stock Details

Ticker Symbol	SYGGF
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00B0381Z20
SIC Code	2836

Key Executives

Name	Position
Richard Marsden	Chief Executive Officer, MD and Executive Director
Prof. Stephen T. Holgate CBE, M.D.	Co-Founder and Member of Scientific Advisory Board
Joseph Tregonning Colliver F.C.A.	Chief Financial Officer and Executive Director
Prof. Donna Davies	Co-Founder and Member of Scientific Advisory Board
Prof. Ratko Djukanovic	Co-Founder and Member of Scientific Advisory Board
Dr. Gareth E. Walters Ph.D.	Chief Regulatory Officer
Jody Brookes	Senior Vice President and Head of Clinical Operations
Richard Francis	Senior Vice President and Head of CMC and Quality
Dr. Victoria Tear	Head of Laboratory
Dr. Marcin Mankowski M.D.	Chief Medical Officer